Dr. Mechoulam unveils synthetic cannabinoids for clinical use

Professor Raphael Mechoulam, 88, who was responsible for the first THC synthesis at CannMed 2019 in Pasadena, California, said he wanted to create stable synthetic cannabinoids

Dr. Mechoulam is working on synthetic cannabinoids. This discovery could pave the way for a whole new line of cannabinoid-based products that can treat a number of medical problems, from arthritis to inflammatory bowel disease.

Find a formula to obtain synthetic and stable acids

"We took the unstable acid molecules from the cannabis plant and synthesized them to provide a stable and consistent basis for new therapies for a wide range of medical needs," Mechoulam said during his presentation to the conference.

This unstable acid molecule is CBD acid (CBDA), a natural precursor of more known CBD. Yet, despite its lower status, CBDA is a thousand times more potent than CBD to bind to a particular serotonin receptor that is believed to be responsible for the relief of nausea and anxiety.

It is this important medical potential that has pushed Mechoulam and his team to eventually stabilize CBDA by adding a methyl ester, making it "a potential drug to treat some nausea and anxiety disorders."

"This is an exciting and unprecedented search," said Mechoulam in a press release. "We took the unstable molecules from the cannabis plant and synthesized them to provide a stable and consistent foundation for new therapies for a wide range of medical needs - from CNS disorders to inflammation and much more.

"In addition, we have provided multiple delivery mechanisms, including tablets, topical applications and many more to facilitate multiple approaches. Our work is a catalyst for the development of new potential therapies from a source long considered to have enormous potential. "

From the laboratories to the sale

In collaboration with the Mechoulam team, the discovery of the CBDA methyl ester was made with the help of several universities in Israel, Canada and the United States, a topical cream manufacturer, a laboratory testing and the young company EPM.

In order to invest more in the molecule, the latter launched last week its portfolio of intellectual property with the health care industry for possible licensing partnerships.

"This marks the beginning of a new era in medical research with the introduction by EPM of the world's first innovative licensing platform for the use of our fully stable acid-based cannabinoid molecules," Reshef said. Swisa, CEO of EPM, in a press release. "The work of our world-class research team has bridged the promise of therapeutic uses of cannabis with the ability of pharmaceutical companies to use stable and consistent molecules that researchers can use to potentially discover new drugs. drugs. "

The company hopes that the first applications of the new compound will enter 1 phase of FDA trials (the US authority in charge of validating drugs) in six to twelve months. Yet, since the average FDA drug approval time is 12 years, it may take some time before clinicians can self-test the benefits of the Mechoulam compound.

Urging the scientific community to further support medical research on cannabis during his speech at the conference, Mr Mechoulam lamented the already lost research time and patients who missed cannabis treatments for diseases such as epilepsy.

"Should we wait 30 years? No, he says. "We could have helped thousands of children, and we have not done it."

Tags : cannabinoids